FDA approves new competitor to $2.1million drug for SMA

FDA approves new competitor to $2.1million drug for SMA

 

Zolgensma came to the market last year as the highest priced drug in the world. This gene therapy costs $2.1 million for a single-dose and it is considered a one-time, long-term treatment for the rare, genetic disease called spinal muscular atrophy (SMA).

The FDA has now approved a new treatment for SMA called Evrysdi. This drug is the first oral medication for SMA and it is taken once a day at home. Evrysdi comes with a price tag that ranges from $100,000 to $340,000 per year depending on weight.

Evrysdi is now the 3rd treatment option for SMA patients, and while it has a lower annual cost than both Zolgensma and Spinraza, it still poses a financial challenge for payers. For comparison, Spinraza is priced at $750,000 in the first year and then $375,000 each following year.

Since Evrysdi is self-administered at home, claims will be processed and paid through the pharmacy benefit rather than the medical benefit for carved-out plans. Reach out to Truveris to review your PBM plan design and ensure appropriate cost management is in place.

 

Topics: Trends, Insights & Analysis, Prescription Drug News & Regulations - Employers

Posted by

Michelle Gerlovin, PharmD.

Senior Client Services Director
Michelle is a clinical pharmacist with a passion for improving outcomes while controlling healthcare costs. She has worked in various pharmacy practice and pharmacy benefit management settings. Michelle's experience includes pharmaceutical rebate analysis, drug utilization management, and strategic pharmacy benefit support for government clients.